Home   Contact Palatin   Site Map  
 

Investor/Media Center

Press Releases

 
2008 2009 2010 2011 2012 2013 2014 all
 
 

 


Displaying releases: 1-40 | 41-80 | 81-120 | 121-160 | 161-182


  Mar-06-2014 Palatin Technologies to present at the 26th Annual ROTH Conference
  Feb-24-2014 Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder
  Feb-18-2014 Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014
  Feb-13-2014 Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results Teleconference and Webcast to be held on February 18, 2014
  Jan-30-2014 Palatin Technologies to Present at the 16th Congress of the European Society for Sexual Medicine
  Jan-23-2014 Palatin Technologies, Inc. Receives $1.85 Million from Sale of New Jersey State Tax Credits
  Jan-16-2014 Palatin Technologies to Present at “TEN”, Noble Financial Capital Markets’ Tenth Annual Equity Conference
  Jan-13-2014 Palatin Technologies Responds to Unusual Market Activity
  Dec-02-2013 Palatin Technologies To Participate In The 25th Annual Piper Jaffray Healthcare Conference
  Nov-14-2013 Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
  Nov-13-2013 Palatin Technologies Announces Option for License to Bremelanotide in Europe
  Nov-12-2013 Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
  Nov-11-2013 Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results Teleconference and Webcast to be held on November 14, 2013
  Oct-28-2013 Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
  Oct-04-2013 PALATIN TECHNOLOGIES TO PRESENT AT THE 12TH ANNUAL BIO INVESTOR FORUM
  Sep-30-2013 Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
  Sep-25-2013 Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results Teleconference and Webcast to be held on October 1, 2013
  May-14-2013 Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
  May-08-2013 Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
  May-02-2013 Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
  Mar-19-2013 Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
  Mar-15-2013 PALATIN TECHNOLOGIES TO PRESENT AT THE 25TH ANNUAL ROTH CONFERENCE
  Mar-04-2013 PALATIN TECHNOLOGIES, INC. TO PRESENT AT THE COWEN & COMPANY 33rd ANNUAL HEALTH CARE CONFERENCE
  Mar-01-2013 Palatin Technologies Presents Positive Data for Bremelanotide in Female Sexual Dysfunction
  Feb-14-2013 Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
  Feb-08-2013 Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
  Feb-07-2013 PALATIN TECHNOLOGIES, INC. TO PRESENT AT 15TH ANNUAL BIO CEO & INVESTOR CONFERENCE
  Jan-03-2013 Palatin Technologies Receives $1.75 Million from Sale Of New Jersey State Tax Credits
  Nov-21-2012 Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
  Nov-14-2012 Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
  Nov-12-2012 Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
  Nov-09-2012 Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
  Nov-08-2012 Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
  Sep-11-2012 Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
  Sep-10-2012 Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
  Sep-07-2012 Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
  Sep-06-2012 Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
  Jul-02-2012 Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
  Jun-19-2012 Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
  May-14-2012 Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012